Medical device company Neovasc Inc (NASDAQ:NVCN) (TSX:NVCN) reported on Wednesday the US Food and Drug Administration's (the FDA) breakthrough device designation for the Neovasc Reducer (the Reducer) in order to expedite the development and review of the device for the treatment of refractory angina.
The company stated that Reducer is not currently commercially available in the US, but has been commercially available in Europe since 2015.
According to the company, refractory angina is a painful and debilitating condition that occurs when the coronary arteries deliver an inadequate supply of blood to the heart muscle, despite treatment with standard revascularization or cardiac drug therapies. The Reducer provides relief of angina symptoms by altering blood flow in the heart's circulatory system, thereby increasing the perfusion of oxygenated blood to ischemic areas of the heart muscle.
In conjunction, the placement of the Reducer is performed using a minimally invasive transvenous procedure that is similar to implanting a coronary stent and is completed in approximately 20 minutes, concluded the company.
The US FDA approves ID CORE XT for testing blood compatibility in transfusion medicine
Celltrion and Teva Pharmaceutical's Rituxan biosimilar receives US FDA approval recommendation
Otsuka partners with Proteus Digital Health to advance digital medicines in mental health
Neovasc awarded US FDA's breakthrough device designation for the Neovasc Reducer
SpineEX wins US FDA's clearance for Sagittae lateral lumbar Interbody fusion device
Genentech to Present New Positive Data from Its Broad Cancer Immunotherapy Programme
European Medicines Accepts Drug Application for Aerie Pharmaceuticals' Rhokiinsa